Fumonisins

• 

  Subject Areas on Research

  • A blood spot method for detecting fumonisin-induced changes in putative sphingolipid biomarkers in LM/Bc mice and humans. 
  • Acylation of naturally occurring and synthetic 1-deoxysphinganines by ceramide synthase. Formation of N-palmitoyl-aminopentol produces a toxic metabolite of hydrolyzed fumonisin, AP1, and a new category of ceramide synthase inhibitor. 
  • Alteration in sphingolipid metabolism: bioassays for fumonisin- and ISP-I-like activity in tissues, cells and other matrices. 
  • Alteration of tissue and serum sphinganine to sphingosine ratio: an early biomarker of exposure to fumonisin-containing feeds in pigs. 
  • Characterization of cell-cycle arrest by fumonisin B1 in CV-1 cells. 
  • Chronic toxicity of fumonisins from Fusarium moniliforme culture material (M-1325) to mink. 
  • Dietary fumonisin B1 induces disruption of sphingolipid metabolism in Sprague-Dawley rats: a new mechanism of nephrotoxicity. 
  • Effects of feeding Fusarium moniliforme culture material, containing known levels of fumonisin B1, on the young broiler chick. 
  • Evidence for disruption of sphingolipid metabolism as a contributing factor in the toxicity and carcinogenicity of fumonisins. 
  • Evidence for fumonisin inhibition of ceramide synthase in humans consuming maize-based foods and living in high exposure communities in Guatemala. 
  • Exposure to fumonisins and the occurrence of neural tube defects along the Texas-Mexico border. 
  • Fumonisin B1 alters sphingolipid metabolism and disrupts the barrier function of endothelial cells in culture. 
  • Fumonisin B1 consumption by rats causes reversible, dose-dependent increases in urinary sphinganine and sphingosine. 
  • Fumonisin B1 inhibits sphingosine (sphinganine) N-acyltransferase and de novo sphingolipid biosynthesis in cultured neurons in situ. 
  • Fumonisin inhibition of de novo sphingolipid biosynthesis and cytotoxicity are correlated in LLC-PK1 cells. 
  • Fumonisin toxicity and sphingolipid biosynthesis. 
  • Fumonisins and fumonisin analogs as inhibitors of ceramide synthase and inducers of apoptosis. 
  • Fumonisins disrupt sphingolipid metabolism, folate transport, and neural tube development in embryo culture and in vivo: a potential risk factor for human neural tube defects among populations consuming fumonisin-contaminated maize. 
  • Hydrolyzed fumonisins HFB1 and HFB2 are acylated in vitro and in vivo by ceramide synthase to form cytotoxic N-acyl-metabolites. 
  • In vitro toxicology of fumonisins and the mechanistic implications. 
  • Increases in serum sphingosine and sphinganine and decreases in complex sphingolipids in ponies given feed containing fumonisins, mycotoxins produced by Fusarium moniliforme. 
  • Inhibition of sphingolipid biosynthesis by fumonisins. Implications for diseases associated with Fusarium moniliforme. 
  • Prevention of fumonisin B1-induced neural tube defects by folic acid. 
  • Role of dietary sphingolipids and inhibitors of sphingolipid metabolism in cancer and other diseases. 
  • Sphingolipid biosynthesis de novo by rat hepatocytes in culture. Ceramide and sphingomyelin are associated with, but not required for, very low density lipoprotein secretion. 
  • Sphingolipid metabolism: roles in signal transduction and disruption by fumonisins. 
  • Sphingolipids as biomarkers of fumonisin exposure and risk of esophageal squamous cell carcinoma in china. 
  • Sphingosine-1-phosphate phosphohydrolase regulates endoplasmic reticulum-to-golgi trafficking of ceramide. 
  • The effect of fumonisin B1 on developing chick embryos: correlation between de novo sphingolipid biosynthesis and gross morphological changes. 
  • The kinetics of urinary fumonisin B1 excretion in humans consuming maize-based diets. 
  • Two mammalian longevity assurance gene (LAG1) family members, trh1 and trh4, regulate dihydroceramide synthesis using different fatty acyl-CoA donors. 
  • Urinary fumonisin B1 and estimated fumonisin intake in women from high- and low-exposure communities in Guatemala.